X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with Glenmark Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON LTD vs GLENMARK PHARMA - Comparison Results

BIOCON LTD    Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON LTD GLENMARK PHARMA BIOCON LTD/
GLENMARK PHARMA
 
P/E (TTM) x 82.9 12.2 679.3% View Chart
P/BV x 7.8 3.2 242.0% View Chart
Dividend Yield % 0.2 0.4 42.4%  

Financials

 BIOCON LTD   GLENMARK PHARMA
EQUITY SHARE DATA
    BIOCON LTD
Mar-17
GLENMARK PHARMA
Mar-17
BIOCON LTD/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs1,162993 117.0%   
Low Rs483729 66.2%   
Sales per share (Unadj.) Rs194.6325.5 59.8%  
Earnings per share (Unadj.) Rs34.439.3 87.6%  
Cash flow per share (Unadj.) Rs48.348.7 99.2%  
Dividends per share (Unadj.) Rs1.002.00 50.0%  
Dividend yield (eoy) %0.10.2 52.4%  
Book value per share (Unadj.) Rs241.9159.2 151.9%  
Shares outstanding (eoy) m200.00282.17 70.9%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.22.6 159.8%   
Avg P/E ratio x23.921.9 109.0%  
P/CF ratio (eoy) x17.017.7 96.3%  
Price / Book Value ratio x3.45.4 62.8%  
Dividend payout %2.95.1 57.1%   
Avg Mkt Cap Rs m164,440242,991 67.7%   
No. of employees `0009.213.0 71.2%   
Total wages/salary Rs m7,47016,408 45.5%   
Avg. sales/employee Rs Th4,213.97,083.9 59.5%   
Avg. wages/employee Rs Th809.01,265.4 63.9%   
Avg. net profit/employee Rs Th745.2855.1 87.2%   
INCOME DATA
Net Sales Rs m38,91191,857 42.4%  
Other income Rs m1,571374 420.4%   
Total revenues Rs m40,48292,230 43.9%   
Gross profit Rs m9,79520,367 48.1%  
Depreciation Rs m2,7722,644 104.9%   
Interest Rs m2602,373 11.0%   
Profit before tax Rs m8,33415,724 53.0%   
Minority Interest Rs m1630-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-810 0.0%   
Tax Rs m1,6163,827 42.2%   
Profit after tax Rs m6,88111,088 62.1%  
Gross profit margin %25.222.2 113.5%  
Effective tax rate %19.424.3 79.7%   
Net profit margin %17.712.1 146.5%  
BALANCE SHEET DATA
Current assets Rs m40,47768,746 58.9%   
Current liabilities Rs m16,78327,027 62.1%   
Net working cap to sales %60.945.4 134.1%  
Current ratio x2.42.5 94.8%  
Inventory Days Days6085 70.1%  
Debtors Days Days8396 86.7%  
Net fixed assets Rs m45,07324,132 186.8%   
Share capital Rs m1,000282 354.4%   
"Free" reserves Rs m47,37744,643 106.1%   
Net worth Rs m48,37744,925 107.7%   
Long term debt Rs m21,08245,363 46.5%   
Total assets Rs m93,942117,639 79.9%  
Interest coverage x33.17.6 433.5%   
Debt to equity ratio x0.41.0 43.2%  
Sales to assets ratio x0.40.8 53.0%   
Return on assets %7.611.4 66.4%  
Return on equity %14.224.7 57.6%  
Return on capital %12.619.1 65.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m12,98856,152 23.1%   
Fx outflow Rs m7,8998,084 97.7%   
Net fx Rs m5,08948,068 10.6%   
CASH FLOW
From Operations Rs m6,4006,574 97.3%  
From Investments Rs m-4,985-7,124 70.0%  
From Financial Activity Rs m-1,7755,432 -32.7%  
Net Cashflow Rs m-4731,992 -23.7%  

Share Holding

Indian Promoters % 40.4 48.3 83.6%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 6.9 121.7%  
FIIs % 10.7 34.4 31.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 10.5 189.5%  
Shareholders   109,995 56,727 193.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON LTD With:   ABBOTT INDIA  JUBILANT LIFE SCIENCES  DIVIS LABORATORIES  PFIZER  ALKEM LABORATORIES  

Compare BIOCON LTD With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Strong Finish to the Week; Metal & Pharma Stocks Gain(Closing)

Indian share markets finished the trading session on a strong note amid firm Asian markets after comments from a Federal Reserve official eased worries about faster rate hikes in US.

Related Views on News

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON LTD SHARE PRICE


Feb 23, 2018 (Close)

TRACK BIOCON LTD

  • Track your investment in BIOCON LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE BIOCON LTD WITH

MARKET STATS